LANXESS CMIT/MIT Biocides: What Changes in EU Authorization and What Companies Must Review

Key data

If your company manufactures, distributes, or industrially uses CMIT/MIT-based biocides, this modification directly affects you. The Implementing Regulation (EU) 2026/2024, published on 11 September 2026 and in force since 10 September, introduces changes to the Union authorization for the LANXESS CMIT/MIT biocides family. The regulation being modified is Implementing Regulation (EU) 2024/2750.

Although the changes are described as "administrative and minor," ignoring them is not an option: marketing a biocide with documentation or labeling that does not reflect the current authorization can result in sanctions or product withdrawal from the market.

What does this regulation establish?

The regulation modifies the Union authorization framework for the LANXESS CMIT/MIT biocides family. The changes introduced fall into two categories:

It is important to emphasize what does not change: the active substance (CMIT/MIT) and the authorized uses for this biocides family remain unchanged. CMIT/MIT are widely used preservatives in three major areas:

• Industrial products (cutting fluids, paints, adhesives, industrial cleaning products)
• Cosmetics and personal care products
• Water treatment

The previous reference standard was Implementing Regulation (EU) 2024/2750, which established the original Union authorization for this product family. The new regulation 2026/2024 does not repeal it, but modifies it specifically in the administrative and minor aspects described.

Economic and operational impact

As these are administrative and minor changes, the direct economic impact is limited. However, the operational cost of adaptation can be significant for companies with large product volumes or complex labeling and documentation processes. The main cost drivers are:

• Labeling review and update: If changes affect labeling conditions, it will be necessary to update labels on products marketed under this authorization.
• Compliance documentation update: Safety data sheets, internal records and technical documentation must reflect the current authorization.
• Supply chain communication: Distributors and industrial users must be informed of any changes affecting the products they receive or use.
• Non-compliance risk: Marketing products with outdated documentation or labeling can result in sanctions from competent authorities or product withdrawal from the market.

The cost of inaction far exceeds the cost of adaptation: a market withdrawal or sanction for regulatory non-compliance results in economic and reputational losses far greater than the effort to review documentation.

Who does it affect?

• CMIT/MIT biocides manufacturers: Must verify whether changes in holder data, minor composition or labeling directly affect them and update their authorization documentation.
• Biocides distributors in the EU: Must ensure that the products they market comply with the updated authorization, including current labeling.
• Industrial users: Companies that use CMIT/MIT as a preservative in their processes (manufacturers of paints, adhesives, industrial fluids, cosmetic products, water treatment plants) must verify that their suppliers provide them with products compliant with the new authorization.
• Compliance and operations directors in chemical, cosmetic and industrial sector companies.
• Regulatory advisors who manage biocides authorizations for their clients.

Practical example

A company manufacturing cutting fluids for the metalworking industry uses CMIT/MIT as a preservative in its formulation, covered by the Union authorization for the LANXESS CMIT/MIT family (Regulation (EU) 2024/2750).

Following the publication of Regulation (EU) 2026/2024, the company's compliance officer must:

1. Access the text of the new regulation and compare it with the previous authorization to identify exactly what holder data or labeling conditions have changed.
2. Review current product labels to verify whether they reflect updated labeling conditions.
3. Update safety data sheets if changes in minor composition require it.
4. Communicate to distributor customers any changes in product labeling or documentation.

If the company does not conduct this review and continues to market the product with documentation based solely on Regulation (EU) 2024/2750 without incorporating the modifications of 2026/2024, it exposes itself to a non-compliance situation during an inspection by competent authorities.

What should companies do now?

1. Consult the full text of Regulation (EU) 2026/2024 in the EU Official Journal to identify exactly what aspects of the authorization have changed compared to Regulation (EU) 2024/2750.
2. Review internal compliance documentation (safety data sheets, authorization records, technical documentation) and verify whether it needs to be updated.
3. Check current labeling of products marketed under this authorization and adapt labels if labeling conditions have changed.
4. Inform the supply chain: If you are a manufacturer, communicate the changes to your distributors. If you are a distributor, verify with your supplier that received products comply with the updated authorization.
5. Update internal records for managing biocides authorizations to reflect the new regulatory reference (Regulation (EU) 2026/2024).
6. Consult a regulatory advisor specialized in biocides if there are doubts about the scope of changes in minor composition or labeling conditions applicable to your specific products.

Official source

Consult full regulation in official source

Disclaimer: This article is for informational purposes only and does not constitute legal advice. For specific decisions, consult a qualified professional. Source: https://eur-lex.europa.eu/./legal-content/AUTO/?uri=OJ:L_202602024